Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTC Therapeutics, Inc. (PTCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation listed on the Nasdaq Global Select Market under the symbol PTCT, PTC uses SEC reports to communicate material events, financial results and key agreements related to its rare disease biopharmaceutical business.
Among the filings, investors can find Form 8-K current reports detailing quarterly financial results, such as revenue from Sephience (sepiapterin), the Duchenne muscular dystrophy franchise (Translarna and Emflaza), and royalty and collaboration revenue including Evrysdi (risdiplam). 8-K filings also describe significant corporate events, including FDA approvals like the U.S. approval of Sephience for phenylketonuria (PKU), regulatory correspondence such as a Complete Response Letter for vatiquinone in Friedreich’s ataxia, and material agreements like the Rights Satisfaction Agreement with former Censa securityholders related to sepiapterin net sales payments.
Through its periodic reports (such as Forms 10-K and 10-Q, when available), PTC Therapeutics provides more extensive information on its business, risk factors, R&D and SG&A expenses, cash position, royalty and collaboration structures, and the status of programs including Translarna, Emflaza, Sephience, votoplam, vatiquinone, Upstaza/Kebilidi, Tegsedi and Waylivra. These filings also confirm the company’s incorporation in Delaware and its principal executive offices in Warren, New Jersey.
Stock Titan enhances access to PTCT filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand revenue composition, major agreements, regulatory developments and forward-looking statements. Real-time updates from EDGAR mean new 8-Ks, 10-Qs, 10-Ks and other forms appear promptly, while Form 4 insider transaction reports and proxy materials, when filed, can offer additional insight into equity awards, executive compensation and ownership changes.
By using this filings page, investors and researchers can review the official record of how PTC Therapeutics describes its rare disease portfolio, collaborations, financial performance and risks in its own words to U.S. regulators.
Mark Elliott Boulding, Executive Vice President and CLO of PTC Therapeutics, Inc. (PTCT), reported multiple share transactions effected under a written Rule 10b5-1 plan adopted December 5, 2024. On September 11 and 12, 2025 he exercised and purchased common stock via stock options priced at $38.10 and simultaneously sold portions of his holdings in a series of transactions with weighted average sale prices ranging from $61.00 to $62.18 per share. Following the reported trades, the filing shows beneficial ownership of 103,901 common shares. The form also discloses outstanding stock options exercisable into specific share amounts with an expiration date of January 6, 2032 and vesting tied to a grant from January 7, 2022.
PTC Therapeutics director David P. Southwell reported option exercise and concurrent sale on 09/09/2025. He exercised 12,000 stock options16,850 shares beneficially owned following the transactions and that the exercised options were currently exercisable. The reporting was made by attorney-in-fact Avraham S. Adler on 09/11/2025. The seller undertakes to provide trade-level details on request to the SEC.
Form 144 notice for PTC Therapeutics, Inc. (PTCT): An individual proposes to sell 22,664 shares of common stock, with an aggregate market value of $1,382,537.32, on or about 09/11/2025 through Fidelity Brokerage Services (NASDAQ). The filing shows the shares were acquired as an option granted on 01/07/2022 and payment is expected in cash upon sale. The issuer has 79,438,094 shares outstanding, and the filing also discloses a recent sale by Mark Boulding of 2,813 shares on 08/15/2025 for gross proceeds of $136,646.45. The filer attests they are not aware of undisclosed material adverse information.
PTC Therapeutics (PTCT) filed a Rule 144 notice reporting a proposed sale of 15,705 common shares through Fidelity Brokerage Services on 09/11/2025 with an aggregate market value of $934,447.50. The filing lists multiple prior acquisitions of the shares primarily from restricted stock vesting in 2023 and 2024 and from option exercises/grants with specified acquisition dates and quantities. The seller represents they are unaware of undisclosed material adverse information and the form indicates no sales by the person in the prior three months.
PTC Therapeutics insider transactions on 09/08/2025: Eric Pauwels, the company's Chief Business Officer and a director, executed a series of option exercises and contemporaneous sales under a Rule 10b5-1 plan adopted June 4, 2025. The filings show multiple option exercises at strike prices between $11.23 and $30.86 that resulted in acquisitions totaling 59,060 shares across several tranches. Simultaneously, Pauwels sold a total of 59,060 shares in multiple trades at weighted average sale prices in the mid-$56 range, reducing his reported beneficial ownership to 72,912 shares. Certain acquired shares include 272 shares from the employee stock purchase plan.
PTC Therapeutics, Inc. (PTCT) filed a Form 144 notice for a proposed sale of 12,000 common shares held at Fidelity Brokerage Services. The filing shows an aggregate market value of $700,128.81 and reports 79,438,094 shares outstanding, with an approximate sale date of 09/09/2025 on NASDAQ. The securities were acquired via an option granted on 01/04/2016 and are to be sold for cash; no sales in the prior three months were reported.
PTC Therapeutics Form 144 filing notifies a proposed sale of 39,850 common shares through Fidelity Brokerage Services with an aggregate market value of $2,268,373.83, intended for sale on 09/08/2025 on NASDAQ. The filing lists four lots acquired via stock options granted in 2016, 2017 and 2018 and shows cash payment on the stated sale date. The filing states there were no securities sold by the reporting person in the prior three months and includes the required attestation that the seller does not possess undisclosed material information. The notice follows Rule 144 disclosure requirements.
PTC Therapeutics insider sale disclosed: Director Allan Steven Jacobson reported a sale of 1,667 shares of PTC Therapeutics (PTCT) on 08/28/2025 at a price of $50.15 per share, reducing his beneficial ownership to 17,451 shares. The Form 4 was signed by an attorney-in-fact on 09/02/2025. The filing is a routine Section 16 disclosure showing an individual director executed a non-derivative sale.
PTC Therapeutics (PTCT) reported a proposed sale under Rule 144 of 1,667 shares of its common stock, with an aggregate market value of $83,601.72. The shares represent restricted stock that vested and were acquired on 06/17/2025 as compensation.
The filing names Fidelity Brokerage Services LLC as the broker and lists an approximate sale date of 08/28/2025 on the NASDAQ. The company’s total shares outstanding are reported as 79,438,094, making the proposed sale a very small fraction of outstanding stock.
PTC Therapeutics insider transactions on 08/15/2025 show Executive Vice President and CLO Mark Elliott Boulding exercised options to buy 2,813 shares at an exercise price of $25.69 and simultaneously sold 2,813 shares at a weighted average sale price of $48.58 per share under a Rule 10b5-1 plan. After the transactions, Mr. Boulding beneficially owned 103,901 shares of common stock and held 24,899 shares subject to unexercised options. The option was originally granted on February 14, 2024, vests over four years with an initial 25% vesting on February 15, 2025 and subsequent 6.25% quarterly vesting starting May 15, 2025. The Rule 10b5-1 plan was adopted December 5, 2024. The sale prices executed ranged from $48.24 to $49.11 and the filer offers to provide per-trade quantities upon request.